J9161 Denileukin Diftitox | HCPCS Reimbursement | OpenPayer

Summary & Overview

HCPCS J9161: Denileukin Diftitox Injection, 1 mcg

HCPCS Level II code J9161 represents denileukin diftitox-cxdl billed per 1 microgram unit, an injectable biologic therapy used in specified clinical contexts. Nationally, accurate coding for high-cost biologics like denileukin diftitox affects claims processing, coverage determinations, and payment consistency across payers. This code is significant for oncology and specialty infusion services where precise unit-based reporting influences reimbursement and utilization tracking.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coding intent, typical sites of service, and payer landscape. The publication outlines benchmarks for unit reporting, common billing modifiers (listed separately), and clinical context for use in outpatient infusion clinics and physician offices. It also summarizes policy considerations that affect prior authorization, medical necessity review, and coverage variability among national commercial plans and Medicare.

This analysis helps billing managers, practice administrators, and revenue cycle staff understand how J9161 is applied, where discrepancies commonly arise, and which topics to prioritize for clean claims and coverage verification. Data not available in the input is noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ9161HCPCS Level IIdenileukin diftitoxinjectionbiologic therapyoncologyinfusion clinicbillingmedical coding

Billing Code Overview

HCPCS Level II code J9161 describes an injectable medication: denileukin diftitox-cxdl, packaged and billed per 1 microgram unit. This code is used to report administration of the specified biologic agent.

Service Type: Injection / Biologic Therapy

Typical Site of Service: Outpatient infusion clinic or physician office

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult with cutaneous T‑cell lymphoma (e.g., persistent/recurrent mycosis fungoides or Sézary syndrome) being treated with systemic immunotoxin therapy. The patient presents to an infusion center or outpatient oncology clinic for administration of J9161 (denileukin diftitox‑cxdl) as an intravenous injection dosed in micrograms. Pre‑visit evaluation includes review of prior therapies, baseline laboratory testing (CBC, CMP), assessment for capillary leak risk, and documentation of informed consent. On the day of service the oncology nurse confirms identity and allergies, establishes IV access, administers premedication per protocol (e.g., antihistamines, acetaminophen, corticosteroid if indicated), and delivers J9161 using an infusion pump or syringe push as specified by the drug preparation instructions. The patient is monitored for infusion reactions, hypotension, fever, rigors, and signs of capillary leak syndrome for the duration of the infusion and for an observation period afterward. Any adverse reactions are documented; in the event of severe reaction the infusion may be slowed, interrupted, or discontinued and appropriate emergency care provided. Post‑infusion documentation includes drug lot number, amount administered in micrograms, any unused drug discarded with modifier JW when applicable, and follow‑up plan for repeat dosing or additional supportive care. Typical sites of service are outpatient oncology infusion centers, hospital outpatient departments, and specialty physician offices with IV infusion capability.

Coding Specifications

Modifier	Description	When to Use

Related Codes

HCPCS-J9059-BENDAMUSTINE-INJECTION-1MG

HCPCS Level II J9059: Bendamustine Hydrochloride Injection, 1 mg

HCPCS-J9060-CISPLATIN-INJECTION-10MG

HCPCS J9060: Cisplatin Injection, 10 mg

HCPCS-J9275-COSIBELIMAB-INJECTION-2MG

HCPCS J9275: Injection of cosibelimab-ipdl, 2 mg

HCPCS-J9100-CYTARABINE-INJECTION-100-MG

HCPCS J9100: Injection, Cytarabine 100 mg

HCPCS-J9030-BCG-INTRAVESICAL-INSTILLATION-1MG

HCPCS J9030: BCG Intravesical Instillation, 1 mg

HCPCS-J9229-INOTUZUMAB-OZOGAMICIN-INJECTION-0-1-MG

HCPCS J9229: Inotuzumab Ozogamicin Injection, 0.1 mg

HCPCS-J9329-TISLELIZUMAB-INJECTION-1MG

HCPCS Level II J9329: Injection of tislelizumab-jsgr, 1 mg

HCPCS-J9227-ISATUXIMAB-INJECTION-10MG

HCPCS J9227: Injection, Isatuximab-irfc, 10 mg

HCPCS-J9203-GEMTUZUMAB-OZOGAMICIN-INJECTION-0-1-MG

HCPCS Level II J9203: Gemtuzumab Ozogamicin Injection, 0.1 mg

HCPCS-J9312-RITUXIMAB-INJECTION-10MG

HCPCS J9312: Rituximab Injection, 10 mg

Showing 1–10 of 227

`22`	Increased procedural services	Use when there is a significant, separately billable increase in physician work or resources required for administration beyond typical infusion complexity (document justification).
`23`	Unusual anesthesia	Use if general anesthesia or monitored anesthesia care is required for drug administration and anesthesia is reported separately.
`52`	Reduced services	Use when the full denileukin diftitox service was partially reduced or not completed, with documentation of reason.
`53`	Discontinued procedure	Use if the infusion was started but discontinued due to patient intolerance or adverse event.
`54`	Surgical care only	Not commonly used for this infusion; include only if a separate surgical episode applies.
`55`	Postoperative management only	Not typically applicable; include only if coding part of a global surgical package.
`56`	Preoperative management only	Rarely applicable; use only when preoperative management is reported separately.
`62`	Two surgeons	Use only if two qualified surgeons are required for an associated procedure documented separately.
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist services for anesthesia	Use if such a clinician provides or assists with anesthesia for the infusion and billing rules permit.
`FY`	Left-hand, first modifier (state/local)	Rarely used; include only per payor/local policy when identifying laterality or facility subunits if applicable.
`JW`	Drug discarded/not administered to any patient	Use when part of the vial/kit is discarded; report drug units administered separately and attach `JW` for discarded portion as required.
`QK`	Medical direction of two, three, or four anesthesia providers	Use when anesthesiologist medical directs multiple CRNAs for anesthesia related to the infusion.
`QX`	CRNA service: CRNA billing for anesthesia services	Use when a CRNA personally performs anesthesia services related to the infusion.
`QY`	Medical direction of one CRNA by an anesthesiologist	Use when physician directs a CRNA for anesthesia provided during infusion.

Taxonomy Code	Specialty	Notes
`208000000X`	Hematology/Oncology	Medical oncology specialists who order and oversee systemic cancer therapies.
`207P00000X`	Dermatology	Dermatologists specializing in cutaneous lymphomas may administer or co-manage therapy.
`363A00000X`	Infusion Therapy	Infusion nurses or infusion clinic providers who perform IV administration and monitoring.
`207L00000X`	Internal Medicine	Hospitalists or internists who may manage inpatient infusions or complications.
`208600000X`	Medical Oncology/ Hematology (combined taxonomy)	Providers with combined focus on hematologic malignancies and systemic therapies.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C84.0`	Mycosis fungoides	Cutaneous T‑cell lymphoma subtype commonly treated with systemic biologic or immunotoxin therapies including denileukin diftitox in selected cases.
`C84.1`	Sézary syndrome	Leukemic variant of cutaneous T‑cell lymphoma where systemic agents such as denileukin diftitox may be considered.
`C84.89`	Other specified lymphomas of skin	Other cutaneous lymphomas that may be indications for specialized systemic therapy.
`C83.9`	Non‑Hodgkin lymphoma, unspecified	Systemic T‑cell lymphomas occasionally managed with targeted biologic agents depending on subtype.
`D47.Z1`	Monoclonal gammopathy, unspecified	Included as a relevant hematologic disorder for monitoring but not a direct indication; occasionally present as comorbidity in oncology patients.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`36415`	Collection of venous blood by venipuncture	Pre‑infusion laboratory sampling (CBC, CMP) for baseline assessment and monitoring.
`96365`	Intravenous infusion, initial, up to 1 hour	Use for billing the infusion administration of the first hour of an injected systemic drug when appropriate per payer guidelines.
`96366`	Intravenous infusion, each additional hour	Use for additional continuous infusion time beyond the initial hour when the drug administration requires extended infusion.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	May be used for concurrent supportive injections (e.g., antiemetics, growth factors) if applicable and coded separately.
`96413`	Chemotherapy administration, intravenous infusion technique; more than 1 hour, single or initial substance/drug	Used by some practices for billing IV chemotherapy/biologic infusion when administration time and payer rules align with this descriptor.